Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB

NCT06205589 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

1500

Enrollment

NETWORK

Sponsor class

Conditions

Tuberculosis, Pulmonary

Interventions

BIOLOGICAL: ID93 + GLA-SE vaccine
BIOLOGICAL: Placebo vaccine

Sponsor

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Collaborators

[object Object]